Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck KGaA Add to portfolio

DAXX:MRK, Jul 15, 11:59 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Wednesday, July 08


News

Merck Announces Appointment of Organon & Co. General Counsel

MRK

In her new role, Deb will act as senior legal advisor to the Board of Directors, Chief Executive Officer and senior management and will be responsible for the company’s worldwide legal affairs, compliance and global environmental health & safety. She will join Organon from Sorrento Therapeutics where she served as Senior Vice President, General Counsel and Corporate Secretary leading the legal, compliance, human resource and quality functions. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, June 30


News

The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test

MRK

Altimmune Inc (NASDAQ: ALT) (received $4.7 million in DoD funding for its Phase 1/2 clinical trial of T-COVID, an investigational intranasal immune modulator for the treatment of outpatients with early COVID-19). Halozyme Therapeutics, Inc. (NASDAQ: HALO) (announced FDA nod for Roche Holdings AG's Basel ADR Common Stock (OTC: RHHBY) Phesgo injection that uses Halozyme's Enhanze technology for treating early and metastatic HER2-positive breast cancer). Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) (announced positive data from Phase 3 study of rilonacept in recurrent pericarditis). Verrica Pharmaceuticals Inc (NASDAQ: VRCA) said it has received a letter from the FDA regarding the NDA for VP-102, its lead drug candidate for the treatment of molluscum contagiosum, stating there are deficiencies in the application that ruled out discussion of labeling and post-marketing requirements/commitments at this time.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, June 25


News

The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy

MRK

Gene therapy company Uniqure NV (NASDAQ: QURE) said it has entered into a licensing agreement with CSL Behring, providing the latter with exclusive global rights to etranacogene dezaparvovec, uniQure's investigational gene therapy for patients with hemophilia B. UniQure said the proposed transaction will provide significant financial resources to advance and expand its pipeline of gene therapy candidates, anchored by AMT-130 in Huntington's disease, and to invest further in its leading gene therapy manufacturing and technology platform to support pipeline growth. After protracted three-way wrangling, Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) clinched a definitive merger agreement to be bought by La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $43 million in upfront cash, plus potential future cash payments of up to $16 million pursuant to contingent value rights. HUTCHISON CHINA/S ADR (NASDAQ: HCM) announced that it has entered into a definitive agreement for the sale of $100 million of shares at $25 per ADS through a private placement to private equity firm General Atlantic.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, June 18


News

The Zacks Analyst Blog Highlights: Merck, CVS Health, Morgan Stanley, Applied Materials and Enterprise Products Partners

MRK MS +1 more MRK MS CVS

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck MRK, CVS Health CVS, Morgan Stanley MS, Applied Materials AMAT and Enterprise Products Partners EPD. Merck shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-10% vs. +5.1%), but the Zacks analyst believes that the company's outlook remains favorable given products like Keytruda, Lynparza and Bridion. The potential separation into two companies makes strategic sense as the remaining Merck should be able to achieve higher profits than the combined company. However, Merck expects COVID-related business disruptions to impact sales in its Pharmaceuticals as well as Animal Health units in 2020 with maximum impact in the second quarter.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, June 17


News

Top Stock Reports for Merck, CVS & Morgan Stanley

MRK MS +1 more MRK MS CVS

Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), CVS Health (CVS) and Morgan Stanley (MS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. Merck shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-10% vs. +5.1%), but the Zacks analyst believes that the company's outlook remains favorable given products like Keytruda, Lynparza and Bridion. Shares of CVS have lost -11.1% over the past six months against the Zacks Retail Pharmacies and Drug Stores industry’s fall of -15.2%.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Merck Prices $4.5 Billion Debt Offering

MRK

The offering is expected to close on June 24, 2020, subject to customary closing conditions. The offering may be made only by means of a prospectus and related prospectus supplement, copies of which may be obtained by calling BNP Paribas Securities Corp. toll-free at 1-800-854-5674, BofA Securities, Inc. collect at 1-800-294-1322, Citigroup Global Markets Inc. toll-free at 1-800-831-9146 or Deutsche Bank Securities Inc. toll-free at 1-800-503-4611. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA.

Read Full Details

Topics:
  • Business
  • Financial
  • Health

Wednesday, June 10


News

The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset

MRK

IMMURON LTD/S ADR (NASDAQ: IMRN)( reacted to an award of a $3.7 million in DoD funding for a new candidate that offers protection against travelers' diarrhea). With the two-way contest for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) ending after AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) pulled out, Melinta announced a definitive merger agreement to acquire Tetraphase, through a tender offer, for an aggregate of $39 million in cash, plus an additional $16 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition. Women's health company Vermillion, Inc. (NASDAQ: VRML) announced it is set to join the broad-market Russell 3000 Index, effective after the market opens on June 29. The stock soared 88.52% to $2.30 in after-hours trading, adding to the nearly 42% jump in regular session.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, June 04


News

The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

MRK AZN +1 more MRK AZN AZN

The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic. Black Diamond Therapeutics Inc (NASDAQ: BDTX). Fortress Biotech (NASDAQ: FBIO). Following a bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) that saw the contenders sweetening their offers a few times, AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), one of the contenders, said it does not intend to revise further its offer and that the offer is likely to be terminated by Tetraphase. Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the FDA has issued an Emergency Use Authorization for the Elecsys IL-6 test, which measures levels of the biomarker interleukin 6 and can be used to help identify patients with confirmed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. AstraZeneca Announces Oncology Partnership With Accent For Up To $1.2B. AstraZeneca plc (NYSE: AZN) announced a collaboration with Accent Therapeutics to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins for the treatment of cancer.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, June 03


News

Top Stock Reports for Alibaba, UnitedHealth & Merck

MRK UNH

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), UnitedHealth (UNH) and Merck (MRK). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. This is aiding growth in Tmall Import, Hema fresh food grocery business and Intime Department Stores. However, higher costs associated with new initiatives remain a major concern. The Zacks analyst believes that the company has been benefiting from higher segmental contributions, which helped it counter the fallout from the coronavirus-led crunch.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, June 02


News

World Markets for Interferons, 2030 (COVID-19 Adjusted) - Roche, Merck, BMS, Biogen, Bayer, Zydus Cadila, Novartis, Pfizer, Biosidus, and Nanogen are the Major Players

MRK PFE +2 more MRK PFE BAYN BIIB

DUBLIN, June 2, 2020 /PRNewswire/ -- The "Interferons Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering. This is because of the ongoing trials on various drug candidates including interferons as potential therapeutic options for COVID-19 treatment. The drug regulators including the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) have approved the initiation of trials evaluating interferons. For example, SNG001 which is an inhalation formulation of interferon-beta-1a that is delivered to the lungs directly via nebulization. Due to the high R&D costs, and lengthy testing and manufacturing process, the marketed drugs would be priced much higher than the actual manufacturing costs, and this factor is likely to challenge the market growth.

Read Full Details

Topics:
  • Business
  • Health